寡进行性非小细胞肺癌的立体定向消融放疗 (SUPPRESS-NSCLC)
非小细胞肺癌全身治疗难治性寡进展性疾病的立体定向消融放疗:一项基于注册的 II 期随机试验
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、H2X 3E4
- Centre Hospitalier de l'Université de Montréal
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years
- Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry
- Ability to provide written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3
- Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.
- Oligoprogression while on systemic therapy (any line)
- Patients with brain metastasis are allowed; brain metastasis are not counted in the maximum number of lesions and should be treated as per standard of care
- All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)
- Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.
Exclusion Criteria:
- Any lesion beyond 5 cm
- Pregnancy or breastfeeding
- Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.
- Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Standard of care
Switch to subsequent systemic therapy line, best supportive care or continue current systemic line |
SABR to all oligoprogressive lesions + continuation of current systemic therapy |
|
实验性的:Experimental SABR arm
Definitive SABR to oligoprogressive lesions + continue current systemic therapy |
Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS
大体时间:5 years
|
PFS defined from randomization to disease progression at any site or death |
5 years
|
|
OS
大体时间:5 years
|
OS defined as time from randomization to time of death from any cause. |
5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Quality of life Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE)
大体时间:5 years
|
Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE) |
5 years
|
|
Quality of life 5-level EQ-5D (EQ-5D-5L)
大体时间:5 years
|
questionnaire |
5 years
|
|
Grade ≥ 3 toxicity
大体时间:5 years
|
Measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0) |
5 years
|
|
Local control
大体时间:5 years
|
Defined as time from the end of SABR treatment to date of local failure and will be measured only in the experimental arm |
5 years
|
|
Time to next systemic therapy
大体时间:5 years
|
Defined as time from randomization to time of subsequent therapy line |
5 years
|
合作者和调查者
调查人员
- 学习椅:Bertrand Routy, MD PhD、Centre hospitalier de l'Université de Montréal (CHUM)
- 学习椅:Houda Bahig, MD PhD、Centre hospitalier de l'Université de Montréal (CHUM)
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.